aTYR PHARMA (ATYR) Invested Capital (2014 - 2020)

aTYR PHARMA (ATYR) has reported Invested Capital for 7 consecutive years, with $35.1 million the latest figure, recorded in Q3 2020.

• For the quarter ending Q3 2020, Invested Capital fell 6.06% year-over-year to $35.1 million; the trailing twelve-month figure through Sep 2020 stood at $35.1 million (down 6.06% YoY), and the FY2019 full-year result was $29.8 million, down 40.09% from the prior year.
• Invested Capital retreated to $35.1 million in Q3 2020 per ATYR's latest filing, from $40.9 million in the prior quarter.
• Across five years, Invested Capital topped out at $104.8 million in Q1 2016 and bottomed at $29.8 million in Q4 2019.
• Historically, Invested Capital has averaged $60.7 million across 5 years, with a median of $56.8 million in 2018.
• The widest YoY moves for Invested Capital: up 218.38% in 2016, down 43.28% in 2016.
• Over 5 years, Invested Capital stood at $72.3 million in 2016, then gained by 16.09% to $84.0 million in 2017, then slumped by 40.84% to $49.7 million in 2018, then tumbled by 40.09% to $29.8 million in 2019, then gained by 17.79% to $35.1 million in 2020.
• According to Business Quant data, Invested Capital over the past three periods registered $35.1 million, $40.9 million, and $48.8 million for Q3 2020, Q2 2020, and Q1 2020 respectively.